Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23424154 | 0.81 | ADORA2A (0.54) | ADORA2AADORA3ADORA2BADORA1MAPT | |
| SCHEMBL28870957 | 0.79 | HTT (0.62) | ADORA2AADORA3ADORA2BADORA1HTT | |
| SCHEMBL2547816 | 0.78 | ADORA2A (0.80) | ADORA2AADORA3ADORA2BADORA1HTT | |
| SCHEMBL961121 | 0.76 | ADORA2A (0.47) | ADORA2AADORA3ADORA2BADORA1HTT | |
| SCHEMBL2550277 | 0.73 | ADORA2A (0.62) | ADORA2AADORA3ADORA2BADORA1HTT | |
| SCHEMBL30487821 | 0.73 | ADORA2A (0.71) | ADORA2AADORA3ADORA2BADORA1HTT | |
| Pbf-509 SCHEMBL29421140 | 0.73 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1HTT | |
| SCHEMBL2551552 | 0.73 | ADORA2A (0.71) | ADORA2AADORA3ADORA2BADORA1HTT | |
| Pbf-509 SCHEMBL2546228 | 0.73 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1HTT | |
| SCHEMBL2549963 | 0.73 | ADORA2A (0.71) | ADORA2AADORA3ADORA2BADORA1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058326-A1 | Pyrimidines, methods for the production thereof, and use thereof | BASF AKTIENGESLLSCHAFT (DE) | 2006-03-16 | — | — | US | disclosed |
| EP-1592695-A1 | PYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069846-A1 | PYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058326-A1 | Pyrimidines, methods for the production thereof, and use thereof | CBR3, CBR1, C5 | ADORA2A 838/4885ADORA3 477/4885ADORA2B 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.